Table 3. Comparison of clinical outcomes in DCM patients with or without truncating variants.

Characteristic	Carrier	Non-carrier	p value	Truncation	Non-truncation	p value
Patients, n	33	37		11	59
Age of onset, y	53.4	52.7	0.838	52.0	53.2	0.788
NYHA III or IV, %	6 (20.0%)	9 (30.6%)	0.333	2 (22.2%)	15 (20.3%)
LVEDD, mm	62.9	68.6	0.015	62.4	66.6	0.18
LA, mm	44.4	47.0	0.331	46.6	45.7	0.789
LVEF, %	31.0	27.4	0.196	33.6	28.3	0.185
BNP, pg/ml	812	1184	0.284	1121	1002	0.859
Reversibility, %	5 (15.2%)	9 (24.3%)	0.342	1 (9.1%)	13 (22.0%)	0.328
All mortality, %	4 (12.1%)	4 (10.8%)	0.361	1 (9.1%)	7 (11.9%)	0.792
Cardiac mortality, %	2 (6.1%)	3 (8.1%)	0.742	1 (9.1%)	4 (6.8%)	0.947
Stroke, %	1 (3.0%)	3 (8.1%)	0.361	0 (0)	4 (6.8%)	0.377
ICD implant, %	6 (18.2%)	9 (24.3%)	0.535	3 (27.3%)	12 (20.3%)	0.609
HF hospitalization, %	5 (15.2%)	11 (29.7%)	0.150	1 (9.1%)	15 (25.4%)	0.240

BNP, B-type natriuretic peptide; DCM, dilated cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LA, Left atrium; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Failure Association functional class.